José Luis G. B.
- Country
- Spain
- Department
- Urology
Research Overview
- Evaluation of Safety and Anti-Tumor Activity of Intravesical TARA-002 in High-Grade Non-Muscle Invasive Bladder Cancer
- Efficacy and Safety of TAR-200 vs. Intravesical Chemotherapy in High-Risk Non-Muscle-Invasive Bladder Cancer Post-BCG Recurrence
- Phase 1/2 Evaluation of Detalimogene Voraplasmid in BCG-Unresponsive and High-Risk Non-Muscle Invasive Bladder Cancer Patients
Data & Insights
Has run more than one trial at 12 of 66 partner sites.
Specializations
Bladder Cancer Research
The investigator specializes in treating non-muscle invasive bladder cancer (NMIBC), with particular emphasis on developing therapeutic solutions for patients with high-risk NMIBC.
- BCG-unresponsive bladder cancer management
- High-grade NMIBC treatments
- Intravesical therapy approaches
Their research explores novel therapeutic interventions for patients who have received prior BCG treatment or are BCG-naïve.
Treatment Innovation
The investigator focuses on evaluating novel therapeutic agents including EG-70 and TARA-002 for intravesical administration in bladder cancer patients.
- Alternative treatment pathways
- Intravesical chemotherapy options
- Treatment response assessment
Their work includes investigating treatment options for patients who are ineligible for or have elected not to undergo radical cystectomy.
Clinical Outcomes
The investigator evaluates therapeutic efficacy through comprehensive assessment of disease-free survival and complete response rates in bladder cancer patients.
- Long-term treatment outcomes
- Safety profile evaluation
- Treatment durability assessment
Their research incorporates various diagnostic methods including cystoscopy, bladder biopsy, and urine cytology for treatment monitoring.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.